

- [14] C.A. Lesburg, R. Radfar, P.C. Weber, Recent advances in the analysis of HCV NS5B RNA-dependent RNA polymerase, *Curr. Opin. Investig. Drugs* 1 (2000) 289–296.
- [15] R. De Francesco, C. Steinkuhler, Structure and function of the hepatitis C virus NS3-NS4A serine proteinase, *Curr. Top. Microbiol. Immunol.* 242 (2000) 149–169.
- [16] S.L. Bogen, A. Arasappan, F. Bennett, K. Chen, E. Jao, Y.T. Liu, R.G. Lovey, S. Venkatraman, W. Pan, T. Parekh, R.E. Pike, S. Ruan, R. Liu, B. Baroudy, S. Agrawal, R. Chase, P. Ingravallo, J. Pichardo, A. Prongay, J.M. Brisson, T.Y. Hsieh, K.C. Cheng, S.J. Kemp, O.E. Levy, M. Lim-Wilby, S.Y. Tamura, A.K. Saksena, V. Girijavallabhan, F.G. Njoroge, Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication, *J. Med. Chem.* 49 (2006) 2750–2757.
- [17] R. Liu, K. Abid, J. Pichardo, V. Paziienza, P. Ingravallo, R. Kong, S. Agrawal, S. Bogen, A. Saksena, K.C. Cheng, A. Prongay, F.G. Njoroge, B.M. Baroudy, F. Negro, In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease, *J. Antimicrob. Chemother.* 59 (2007) 51–58.
- [18] S. Venkatraman, S.L. Bogen, A. Arasappan, F. Bennett, K. Chen, E. Jao, Y.T. Liu, R. Lovey, S. Hendrata, Y. Huang, W. Pan, T. Parekh, P. Pinto, V. Popov, R. Pike, S. Ruan, B. Santhanam, B. Vibulbhan, W. Wu, W. Yang, J. Kong, X. Liang, J. Wong, R. Liu, N. Butkiewicz, R. Chase, A. Hart, S. Agrawal, P. Ingravallo, J. Pichardo, R. Kong, B. Baroudy, B. Malcolm, Z. Guo, A. Prongay, V. Madison, L. Broske, X. Cui, K.C. Cheng, Y. Hsieh, J.M. Brisson, D. Prelusky, W. Korfmacher, R. White, S. Bogdanowich-Knipp, A. Pavlovsky, P. Bradley, A.K. Saksena, A. Ganguly, J. Piwinski, V. Girijavallabhan, F.G. Njoroge, Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[1,1-dimethylethyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection, *J. Med. Chem.* 49 (2006) 6074–6086.
- [19] K. Lin, R.B. Pemi, A.D. Kwong, C. Lin, VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells, *Antimicrob. Agents Chemother.* 50 (2006) 1813–1822.
- [20] H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, J. van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, P.L. Jansen, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study, *Gastroenterology* 131 (2006) 997–1002.
- [21] D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D.R. Cameron, M. Cartier, M.G. Cordingley, A.M. Faucher, N. Goudreau, S.H. Kawai, G. Kukolj, L. Lagace, S.R. LaPlante, H. Narjes, M.A. Poupard, J. Rancourt, R.E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y.S. Tzantrizos, S.M. Weldon, C.L. Yóng, M. Llinas-Brunet, An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus, *Nature* 426 (2003) 186–189.
- [22] C. Pierra, A. Amador, S. Benzaria, E. Cretton-Scott, M. D'Amours, J. Mao, S. Mathieu, A. Moussa, E.G. Bridges, D.N. Standring, J.P. Sommadossi, R. Storer, G. Gosselin, Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine, *J. Med. Chem.* 49 (2006) 6614–6620.
- [23] G. Randall, A. Grakoui, C.M. Rice, Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 235–240.
- [24] S.B. Kapadia, A. Brideau-Andersen, F.V. Chisari, Interference of hepatitis C virus RNA replication by short interfering RNAs, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 2014–2018.
- [25] T. Kanda, R. Steele, R. Ray, R.B. Ray, Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect, *J. Virol.* 81 (2007) 669–676.
- [26] K. Abe, M. Ikeda, H. Dansako, K. Naka, K. Shimotohno, N. Kato, cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells, *Virus Res.* 107 (2005) 73–81.
- [27] S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, K. Lin, NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon, *Antimicrob. Agents Chemother.* 50 (2006) 2976–2982.
- [28] K. Watashi, N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, K. Shimotohno, Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase, *Mol. Cell* 19 (2005) 111–122.
- [29] K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, K. Shimotohno, Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes, *Hepatology* 38 (2003) 1282–1288.
- [30] M. Nakagawa, N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C.H. Chen, Y. Itsui, S. Kakinuma, M. Watanabe, Specific inhibition of hepatitis C virus replication by cyclosporin A, *Biochem. Biophys. Res. Commun.* 313 (2004) 42–47.
- [31] M. Nakagawa, N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C.H. Chen, S. Kakinuma, S. Oooka, S. Maekawa, N. Enomoto, M. Watanabe, Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins, *Gastroenterology* 129 (2005) 1031–1041.
- [32] N. Ishii, K. Watashi, T. Hishiki, K. Goto, D. Inoue, M. Hijikata, T. Wakita, N. Kato, K. Shimotohno, Diverse effects of cyclosporine on hepatitis C virus strain replication, *J. Virol.* 80 (2006) 4510–4520.
- [33] K. Goto, K. Watashi, T. Murata, T. Hishiki, M. Hijikata, K. Shimotohno, Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811, *Biochem. Biophys. Res. Commun.* 343 (2006) 879–884.
- [34] J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, J. Neyts, The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro, *Hepatology* 43 (2006) 761–770.
- [35] K. Inoue, K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, M. Yoshida, Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial, *J. Gastroenterol.* 38 (2003) 567–572.
- [36] K. Inoue, M. Yoshida, Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease, *Transplant. Proc.* 37 (2005) 1233–1234.
- [37] S.I. Nakagawa, T. Umehara, C. Matsuda, S. Kuge, M. Sudoh, M. Kohara, Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice, *Biochem. Biophys. Res. Commun.* 353 (2007) 882–888.
- [38] T. Okamoto, Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K. Moriishi, Y. Matsuura, Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90, *EMBO J.* 25 (2006) 5015–5025.
- [39] L. Waxman, M. Whitney, B.A. Pollok, L.C. Kuo, P.L. Darke, Host cell factor requirement for hepatitis C virus enzyme maturation, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 13931–13935.
- [40] A.M. Domitrovich, K.W. Diebel, N. Ali, S. Sarker, A. Siddiqui, Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication, *Virology* 335 (2005) 72–86.
- [41] J.H. Hoonfagle, K.D. Mullen, D.B. Jones, V. Rustgi, A. Di Bisceglie, M. Peters, J.G. Waggoner, Y. Park, E.A. Jones, Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report, *N. Engl. J. Med.* 315 (1986) 1575–1578.
- [42] H. Dansako, A. Naganuma, T. Nakamura, F. Ikeda, A. Nozaki, N. Kato, Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element, *Virus Res.* 97 (2003) 17–30.
- [43] H. Dansako, K. Naka, M. Ikeda, N. Kato, Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells, *Biochem. Biophys. Res. Commun.* 336 (2005) 458–468.
- [44] K. Naka, H. Dansako, N. Kobayashi, M. Ikeda, N. Kato, Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes, *Virology* 346 (2006) 348–362.
- [45] N. Kato, Molecular virology of hepatitis C virus, *Acta Med. Okayama* 55 (2001) 133–159.
- [46] A. Kasahara, N. Hayashi, N. Hiramatsu, M. Oshita, H. Hagiwara, K. Katayama, M. Kato, M. Masuzawa, H. Yoshihara, Y. Kishida, Y. Shimizu, A. Inoue, H. Fusamoto, T. Kumada, Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with

- chronic hepatitis C: a multicenter randomized controlled trial, *Hepatology* 21 (1995) 291–297.
- [47] K. Namba, K. Naka, H. Dansako, A. Nozaki, M. Ikeda, Y. Shiratori, K. Shimotohno, N. Kato, Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype, *Biochem. Biophys. Res. Commun.* 323 (2004) 299–309.
- [48] K. Naka, K. Abe, K. Takemoto, H. Dansako, M. Ikeda, K. Shimotohno, N. Kato, Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells, *J. Hepatol.* 44 (2006) 869–878.
- [49] K. Naka, K. Takemoto, K. Abe, H. Dansako, M. Ikeda, K. Shimotohno, N. Kato, Interferon resistance of hepatitis C virus replicon-harboring cells is caused by functional disruption of type I interferon receptors, *J. Gen. Virol.* 86 (2005) 2787–2792.
- [50] T. Yokota, N. Sakamoto, N. Enomoto, Y. Tanabe, M. Miyagishi, S. Maekawa, L. Yi, M. Kurosaki, K. Taira, M. Watanabe, H. Mizusawa, Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs, *EMBO Rep.* 4 (2003) 602–608.
- [51] M. Ikeda, K. Abe, H. Dansako, T. Nakamura, K. Naka, N. Kato, Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system, *Biochem. Biophys. Res. Commun.* 329 (2005) 1350–1359.
- [52] K.J. Blight, J.A. McKeating, J. Marcotrigiano, C.M. Rice, Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture, *J. Virol.* 77 (2003) 3181–3190.
- [53] M. Ikeda, M. Yi, K. Li, S.M. Lemon, Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells, *J. Virol.* 76 (2002) 2997–3006.
- [54] T. Pietschmann, V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, R. Bartenschlager, Persistent and transient replication of full-length hepatitis C virus genomes in cell culture, *J. Virol.* 76 (2002) 4008–4021.
- [55] J.T. Guo, V.V. Bichko, C. Seeger, Effect of alpha interferon on the hepatitis C virus replicon, *J. Virol.* 75 (2001) 8516–8523.
- [56] N. Kato, K. Sugiyama, K. Namba, H. Dansako, T. Nakamura, M. Takami, K. Naka, A. Nozaki, K. Shimotohno, Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro, *Biochem. Biophys. Res. Commun.* 306 (2003) 756–766.
- [57] T. Kato, T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, T. Wakita, Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon, *Gastroenterology* 125 (2003) 1808–1817.
- [58] H. Kishine, K. Sugiyama, M. Hijikata, N. Kato, H. Takahashi, T. Noshi, Y. Nio, M. Hosaka, Y. Miyanari, K. Shimotohno, Subgenomic replicon derived from a cell line infected with the hepatitis C virus, *Biochem. Biophys. Res. Commun.* 293 (2002) 993–999.
- [59] K.J. Blight, A.A. Kolykhalov, C.M. Rice, Efficient initiation of HCV RNA replication in cell culture, *Science* 290 (2000) 1972–1974.
- [60] K. Abe, M. Ikeda, H. Dansako, K. Naka, N. Kato, Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA, *Virus Res.* 125 (2007) 88–97.
- [61] V. Lohmann, F. Korner, A. Dobierzewska, R. Bartenschlager, Mutations in hepatitis C virus RNAs conferring cell culture adaptation, *J. Virol.* 75 (2001) 1437–1449.
- [62] T. Pietschmann, A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F.L. Cosset, R. Bartenschlager, Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 7408–7413.
- [63] M. Yi, R.A. Villanueva, D.L. Thomas, T. Wakita, S.M. Lemon, Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 2310–2315.
- [64] T. Hugel, A. Cerny, Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C, *Rev. Med. Virol.* 13 (2003) 361–371.
- [65] S.T. Shi, K.J. Lee, H. Aizaki, S.B. Hwang, M.M. Lai, Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2, *J. Virol.* 77 (2003) 4160–4168.
- [66] H. Aizaki, K.J. Lee, V.M. Sung, H. Ishiko, M.M. Lai, Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts, *Virology* 324 (2004) 450–461.
- [67] J.K. Liao, U. Laufs, Pleiotropic effects of statins, *Annu. Rev. Pharmacol. Toxicol.* 45 (2005) 89–118.
- [68] C. Wang, M. Gale Jr., B.C. Keller, H. Huang, M.S. Brown, J.L. Goldstein, J. Ye, Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication, *Mol. Cell* 18 (2005) 425–434.
- [69] J. Ye, C. Wang, R. Sumpter Jr., M.S. Brown, J.L. Goldstein, M. Gale Jr., Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 15865–15870.
- [70] S.B. Kapadia, F.V. Chisari, Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids, *Proc. Natl. Acad. Sci. U. S. A.* 102 (2005) 2561–2566.
- [71] M. Ikeda, K. Abe, M. Yamada, H. Dansako, K. Naka, N. Kato, Different anti-HCV profiles of statins and their potential for combination therapy with interferon, *Hepatology* 44 (2006) 117–125.
- [72] T.A. Kocarek, M.S. Dahn, H. Cai, S.C. Strom, N.A. Mercer-Haines, Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes, *Drug Metab. Dispos.* 30 (2002) 1400–1405.
- [73] J.J. Feld, J.H. Hoofnagle, Mechanism of action of interferon and ribavirin in treatment of hepatitis C, *Nature* 436 (2005) 967–972.
- [74] K. Naka, M. Ikeda, K. Abe, H. Dansako, N. Kato, Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha, *Biochem. Biophys. Res. Commun.* 330 (2005) 871–879.
- [75] Y. Tanabe, N. Sakamoto, N. Enomoto, M. Kurosaki, E. Ueda, S. Maekawa, T. Yamashiro, M. Nakagawa, C.H. Chen, N. Kanazawa, S. Kakinuma, M. Watanabe, Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha, *J. Infect. Dis.* 189 (2004) 1129–1139.
- [76] J.M. Pawlotsky, H. Dahari, A.U. Neumann, C. Hezode, G. Germanidis, I. Lonjon, L. Castera, D. Dhumeaux, Antiviral action of ribavirin in chronic hepatitis C, *Gastroenterology* 126 (2004) 703–714.
- [77] T.S. Reid, K.L. Terry, P.J. Casey, L.S. Beese, Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity, *J. Mol. Biol.* 343 (2004) 417–433.
- [78] T.L. Gower, B.S. Graham, Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro, *Antimicrob. Agents Chemother.* 45 (2001) 1231–1237.
- [79] L. Potena, G. Frascaroli, F. Grigioni, T. Lazzarotto, G. Magnani, L. Tomasi, F. Coccolo, L. Gabrielli, C. Magelli, M.P. Landini, A. Branzi, Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells, *Circulation* 109 (2004) 532–536.
- [80] J.F. Giguere, M.J. Tremblay, Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1, *J. Virol.* 78 (2004) 12062–12065.
- [81] H. Sakamoto, K. Okamoto, M. Aoki, H. Kato, A. Katsume, A. Ohta, T. Tsukuda, N. Shimma, Y. Aoki, M. Arisawa, M. Kohara, M. Sudoh, Host sphingolipid biosynthesis as a target for hepatitis C virus therapy, *Nat. Chem. Biol.* 1 (2005) 333–337.
- [82] T. Umehara, M. Sudoh, F. Yasui, C. Matsuda, Y. Hayashi, K. Chayama, M. Kohara, Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model, *Biochem. Biophys. Res. Commun.* 346 (2006) 67–73.
- [83] M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncalves Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, J. Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, *N. Engl. J. Med.* 347 (2002) 975–982.
- [84] N.M. Dixit, A.S. Perelson, The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus, *Cell. Mol. Life Sci.* 63 (2006) 832–842.
- [85] S. Crotty, C.E. Cameron, R. Andino, RNA virus error catastrophe: direct molecular test by using ribavirin, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 6895–6900.

- [86] R.E. Lanford, B. Guerra, H. Lee, D.R. Averett, B. Pfeiffer, D. Chavez, L. Notvall, C. Bigger, Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons, *J. Virol.* 77 (2003) 1092–1104.
- [87] M. Hosoya, S. Shigeta, T. Ishii, H. Suzuki, E. De Clercq, Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo, *J. Infect. Dis.* 168 (1993) 641–646.
- [88] H. Ishikawa, Mizoribine and mycophenolate mofetil, *Curr. Med. Chem.* 6 (1999) 575–597.
- [89] K. Yanagida, C. Baba, M. Baba, Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha, *Antivir. Res.* 64 (2004) 195–201.
- [90] M. Saijo, S. Morikawa, S. Fukushi, T. Mizutani, H. Hasegawa, N. Nagata, N. Iwata, I. Kurane, Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus, *Antivir. Res.* 66 (2005) 159–163.
- [91] R. Takhampunya, S. Ubol, H.S. Houng, C.E. Cameron, R. Padmanabhan, Inhibition of dengue virus replication by mycophenolic acid and ribavirin, *J. Gen. Virol.* 87 (2006) 1947–1952.
- [92] M.S. Diamond, M. Zachariah, E. Harris, Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA, *Virology* 304 (2002) 211–221.
- [93] Z.J. Gong, S. De Meyer, C. Clarysse, C. Verslype, J. Neyts, E. De Clercq, S.H. Yap, Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro, *J. Viral Hepatitis* 6 (1999) 229–236.
- [94] C.M. Robertson, L.L. Hermann, K.M. Coombs, Mycophenolic acid inhibits avian reovirus replication, *Antivir. Res.* 64 (2004) 55–61.
- [95] P. Leyssen, J. Balzarini, E. De Clercq, J. Neyts, The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase, *J. Virol.* 79 (2005) 1943–1947.
- [96] J.D. Morrey, D.F. Smee, R.W. Sidwell, C. Tseng, Identification of active antiviral compounds against a New York isolate of West Nile virus, *Antivir. Res.* 55 (2002) 107–116.
- [97] S.D. Henry, H.J. Metselaar, R.C. Lonsdale, A. Kok, B.L. Haagmans, H.W. Tilanus, L.J. van der Laan, Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha, *Gastroenterology* 131 (2006) 1452–1462.
- [98] W. Markland, T.J. McQuaid, J. Jain, A.D. Kwong, Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon, *Antimicrob. Agents Chemother.* 44 (2000) 859–866.
- [99] S. Zhou, R. Liu, B.M. Baroudy, B.A. Malcolm, G.R. Reyes, The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA, *Virology* 310 (2003) 333–342.
- [100] A. Goffard, J. Dubuisson, Glycosylation of hepatitis C virus envelope proteins, *Biochimie* 85 (2003) 295–301.
- [101] C. Chapel, C. Garcia, P. Roingard, N. Zitzmann, J. Dubuisson, R.A. Dwek, C. Trepo, F. Zoulim, D. Durantel, Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles, *J. Gen. Virol.* 87 (2006) 861–871.
- [102] F.H. Duong, V. Christen, M. Filipowicz, M.H. Heim, S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro, *Hepatology* 43 (2006) 796–806.
- [103] G.Z. Leu, T.Y. Lin, J.T. Hsu, Anti-HCV activities of selective polyunsaturated fatty acids, *Biochem. Biophys. Res. Commun.* 318 (2004) 275–280.
- [104] A. Hyman, C. Yim, M. Krajden, S. Read, A.S. Basinski, I. Wanless, G. Levy, J. Heathcote, Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C, *J. Viral Hepatitis* 6 (1999) 329–336.
- [105] E. Foy, K. Li, C. Wang, R. Sumpter Jr., M. Ikeda, S.M. Lemon, M. Gale Jr., Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease, *Science* 300 (2003) 1145–1148.
- [106] E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, J. Tschopp, Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus, *Nature* 437 (2005) 1167–1172.
- [107] N. Kato, T. Nakamura, H. Dansako, K. Namba, K. Abe, A. Nozaki, K. Naka, M. Ikeda, K. Shimotohno, Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture, *J. Gen. Virol.* 86 (2005) 645–656.
- [108] M. Yano, T. Nakamura, K. Abe, H. Dansako, S. Ohkoshi, Y. Aoyagi, N. Kato, Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture, *Antimicrob. Agents Chemother.* 51 (2007) 2016–2027.

DDX3 DEAD-Box RNA Helicase Is Required for Hepatitis C Virus RNA Replication[∇]

Yasuo Ariumi,¹ Misao Kuroki,¹ Ken-ichi Abe,¹ Hiromichi Dansako,¹ Masanori Ikeda,¹
Takaji Wakita,² and Nobuyuki Kato^{1*}

Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558,¹ and Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640,² Japan

Received 11 July 2007/Accepted 5 September 2007

DDX3, a DEAD-box RNA helicase, binds to the hepatitis C virus (HCV) core protein. However, the role(s) of DDX3 in HCV replication is still not understood. Here we demonstrate that the accumulation of both genome-length HCV RNA (HCV-O, genotype 1b) and its replicon RNA were significantly suppressed in HuH-7-derived cells expressing short hairpin RNA targeted to DDX3 by lentivirus vector transduction. As well, RNA replication of JFH1 (genotype 2a) and release of the core into the culture supernatants were suppressed in DDX3 knockdown cells after inoculation of the cell culture-generated HCVcc. Thus, DDX3 is required for HCV RNA replication.

DEAD-box RNA helicases are involved in various RNA metabolic processes, including transcription, translation, RNA splicing, RNA transport, and RNA degradation (9, 20). DDX1 and DDX3, DEAD-box RNA helicases, have been implicated in the replication of human immunodeficiency virus type 1 (HIV-1). Both DDX1 and DDX3 interact with HIV-1 Rev and enhance Rev-dependent HIV-1 RNA nuclear export (10, 24).

On the other hand, DDX3 binds to the hepatitis C virus (HCV) core protein (17, 19, 25), and DDX3 expression is deregulated in HCV-associated hepatocellular carcinoma (HCC) (7, 8). However, the biological function of DDX3 in HCV replication is still not understood. To address this issue, we first used lentivirus vector-mediated RNA interference to stably knock down DDX3 in three HuH-7-derived cell lines: O cells, harboring a replicative genome-length HCV RNA (HCV-O, genotype 1b) (13); sO cells, harboring its sub-genomic replicon of HCV RNA (14); or RSc cured cells, which cell culture-generated HCV (HCVcc) (JFH1, genotype 2a) (23) could infect and effectively replicate in (M. Ikeda et al., unpublished data). Oligonucleotides with the following sense and antisense sequences were used for the cloning of short hairpin RNA (shRNA)-encoding sequences against DDX3 in the lentivirus vector: for DDX3i#3, 5'-GATCCCCGGAGGA AATTATAACTCCCTTCAAGAGAGGGAGTTATAATTT CCTCCTTTTTGGAAA-3' (sense) and 5'-AGCTTTTCCAA AAAGGAGGAAATTATAACTCCCTCTCTGAAGGGA GTTATAATTTCTCCGGG-3' (antisense); for DDX3i#7, 5'-GATCCCCGGTACCCTGCCAAACAAGTTCAAGAG ACTTGTGGCAGGGTGACCTTTTTGGAAA-3' (sense) and 5'-AGCTTTTCCAAAAGGTCACCCTGCCAAACAA

GTCTCTTGAACCTTGTGGCAGGGTGACCGGG-3' (antisense). These oligonucleotides were annealed and sub-cloned into the BglII-HindIII site, downstream from an RNA polymerase III promoter of pSUPER (6). To construct pLV-DDX3i#3 and pLV-DDX3i#7, the BamHI-SalI fragments of the corresponding pSUPER plasmids were subcloned into the BamHI-SalI site of pRDI292 (5), an HIV-1-derived self-inactivating lentivirus vector containing a puromycin resistance marker allowing for the selection of transduced cells. The vesicular stomatitis virus G protein (VSV-G)-pseudotyped HIV-1-based vector system has been described previously (18). We used the second-generation packaging construct pCMV-ΔR8.91 (26) and the VSV-G-envelope plasmid pMDG2. The lentivirus vector particles were produced by transient transfection of 293FT cells with FuGene 6 (Roche).

Western blot analysis of the lysates demonstrated the only trace of DDX3 protein in DDX3 knockdown O cells (DDX3i#3) (Fig. 1A). In this context, the HCV core expression level was significantly decreased in the DDX3 knockdown O cells (Fig. 1A). To further confirm this finding, we examined the level of HCV RNA in these cells. We found that accumulation of genome-length HCV-O RNA was notably suppressed in DDX3 knockdown O cells (Fig. 1B). Furthermore, the efficiency of colony formation in DDX3 knockdown Oc cells (created by eliminating genome-length HCV RNA from O cells by interferon treatment) transfected with the genome-length HCV-O RNA with an adapted mutation at amino acid (aa) position 1609 in the NS3 helicase region (K1609E) (13) was also notably reduced compared with that in control cells (Fig. 1C). In contrast, highly efficient knockdown of an unrelated host factor, poly(ADP-ribose) polymerase 1 (PARP-1) (4), had no observable effects on HCV RNA replication, the efficiency of colony formation, or the core expression level (data not shown), suggesting that our finding was not due to a nonspecific event. Interestingly, accumulation of the sub-genomic replicon RNA (HCV-sO) was also suppressed in DDX3 knockdown sO cells (Fig. 1D). Moreover, we examined the potential role of DDX3 in an HCV infection and produc-

* Corresponding author. Mailing address: Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan. Phone: 81 86 235 7386. Fax: 81 86 235 7392. E-mail: nkato@md.okayama-u.ac.jp.

[∇] Published ahead of print on 12 September 2007.




FIG. 1. Requirement of DDX3 for HCV replication. (A to D) Effect of DDX3 knockdown on HCV RNA replication. (A) Inhibition of DDX3 expression by shRNA-producing lentivirus vector. The results of Western blot analysis of cellular lysates with anti-DDX3 (ProSci), anti-HCV core (CP-9; Institute of Immunology), or an anti- β -actin antibody (Sigma) in O cells expressing shRNA against DDX3 (DDX3i#3) as well as in O cells transduced with a control lentivirus vector (Con) are shown. (B) The level of genome-length HCV RNA was monitored by real-time LightCycler PCR (Roche). Experiments were done in duplicate, and bars represent the mean percentages of HCV RNA. (C) Efficiency of colony formation in DDX3 knockdown cells. In vitro-transcribed ON/C-5B K1609E RNA (2 μ g) was transfected into the DDX3 knockdown Oc cells (DDX3i#3) or the Oc cells transduced with a control lentivirus vector (Con). G418-resistant colonies were stained with Coomassie brilliant blue at 3 weeks after electroporation of RNA. Experiments were done in duplicate, and representative results are shown. (D) The level of subgenomic replicon RNA was monitored by real-time LightCycler PCR. Experiments were done in duplicate, and bars represent the mean percentages of HCV RNA. (E to G) Effect of DDX3 knockdown on HCV infection. (E) Inhibition of DDX3 expression by shRNA-producing lentivirus vector. The results of Western blot analysis of cellular lysates with anti-DDX3 or an anti- β -actin antibody for RSc cells expressing the shRNA DDX3i#3 or DDX3i#7 and for RSc cells transduced with a control lentivirus vector (Con) are shown. (F) The level of genome-length HCV (JFH1) RNA was monitored by real-time LightCycler PCR after inoculation of the cell culture-generated HCVcc. Results from three independent experiments are shown. (G) The levels of the HCV core in the culture supernatants were determined by an enzyme-linked immunosorbent assay (Mitsubishi Kagaku Bio-Clinical Laboratories). Experiments were done in duplicate, and bars represent the mean HCV core protein levels.

tion system (23). We found 80 to 90% reductions in the accumulation of JFH1 RNA and 82 to 94% reductions in the release of the core into the culture supernatants in DDX3 knockdown HuH-7-derived RSc cured cells at 4 days after

inoculation of HCVcc (Fig. 1E to G). Thus, DDX3 seems to be required for HCV RNA replication.

Previously, DDX3 was identified as an HCV core-interacting protein by yeast two-hybrid screening. This interaction required the N-terminal domain of the core (aa 1 to 59) and the C-terminal domain of DDX3 (aa 553 to 622) (17, 19, 25). To determine whether the core can interact with DDX3 regardless of the HCV genotype, we used the HCV-O core (genotype 1b) and the JFH1 core (genotype 2a) (Table 1). We first examined their subcellular localization by confocal laser scanning microscopy as previously described (3). Consistent with previous reports (17, 19, 25), both the HCV-O core and JFH1 core mostly colocalized with DDX3 in the perinuclear region (Fig. 2A). Then we immunoprecipitated lysates from 293FT cells in which hemagglutinin (HA)-tagged DDX3 and HCV-O core, JFH1 core, or their 40-aa N-truncated mutants were overexpressed with an anti-HA antibody. Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 4 mM EDTA, 0.5% NP-40, 10 mM NaF, 0.1 mM Na_3VO_4 , 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride. Lysates were precleared with 30 μ l of protein G-Sepharose (GE Healthcare Bio-Sciences). Precleared supernatants were incubated with 1 μ g of anti-HA antibody (3F10; Roche) at 4°C for 1 h. Following absorption of the precipitates

TABLE 1. Primers used for construction of the HCV core-expressing plasmids^a

Plasmid name	Direction	Primer sequence
pCXbsr/core(HCV-O)	Forward	5'-GGAATTCACCATGAGCACGAATCTAAACCTC-3'
	Reverse	5'-ATAAGAATGCGGCCGCTATCAAGCGGAAGCTGGGATGGT-3'
pcDNA3/core(HCV-O)	Forward	5'-CGGGATCCAAGATGAGCACGAATCTAAACCTCAAAGA-3'
	Reverse	5'-CCGCTCGAGTCAAGCGGAAGCTGGGATGGTCAAA CA-3'
pcDNA3/ Δ core(HCV-O)	Forward	5'-CGGGATCCAAGATGGGCCCCAGGTTGGGTGTGCGC-3'
	Reverse	5'-CCGCTCGAGTCAAGCGGAAGCTGGGATGGTCAAA CA-3'
pcDNA3/core(JFH1)	Forward	5'-CGGGATCCAAGATGAGCACAAATCTAAACCTCAAAGA-3'
	Reverse	5'-CCGCTCGAGTCAAGCAGAGACCGGAACGGTGATGCA-3'
pcDNA3/ Δ core(JFH1)	Forward	5'-CGGGATCCAAGATGGGCCCCAGGTTGGGTGTGCGC-3'
	Reverse	5'-CCGCTCGAGTCAAGCAGAGACCGGAACGGTGATGCA-3'

^a To construct pCXbsr/core(HCV-O), a DNA fragment encoding the core was amplified by PCR from pON/C-5B (13) with the indicated primers. The PCR product was digested with EcoRI-NotI and subcloned into the same site of pCX4bsr (1). To construct pcDNA3/core(HCV-O), pcDNA3/FLAG-core(HCV-O), pcDNA3/ Δ core(HCV-O), and pcDNA3/FLAG- Δ core(HCV-O), DNA fragments encoding the core were amplified by PCR from pON/C-5B (13) with the indicated primer sets. To construct pcDNA3/core(JFH1), pcDNA3/FLAG-core(JFH1), pcDNA3/ Δ core(JFH1), and pcDNA3/FLAG- Δ core(JFH1), DNA fragments encoding the core were amplified by PCR from pJFH1 (23) with the indicated primer sets. The PCR products were digested with BamHI and XhoI and then subcloned into the same site of pcDNA3 (Invitrogen) or pcDNA3-FLAG (2).




FIG. 2. Interaction of the HCV core with DDX3. (A) The HCV core colocalizes with DDX3. 293FT cells cotransfected with 100 ng of pCXbsr/core(HCV-O) or pcDNA3/core(JFH1) and 200 ng of pHA-DDX3 were examined by confocal laser scanning microscopy. Cells were stained with anti-HCV core (CP-9 and CP-11 mixture) and anti-DDX3 antibodies and were then visualized with fluorescein isothiocyanate (DDX3) or Cy3 (core). Images were visualized using confocal laser scanning microscopy (LSM510; Carl Zeiss). The right panels exhibit the two-color overlay images (Merged). Colocalization is shown in yellow. (B) The core binds to DDX3. 293FT cells were cotransfected with 4 μ g of pHA-DDX3 and 4 μ g of pCXbsr/core(HCV-O) (wt), pcDNA3/ Δ core(HCV-O) (Δ), pcDNA3/core(JFH1) (wt), or pcDNA3/ Δ core(JFH1) (Δ). The cell lysates were immunoprecipitated with an anti-HA antibody (3F10; Roche), followed by immunoblot analysis using either anti-HA (HA-7; Sigma) or anti-HCV core antibody (CP-9 and CP-11 mixture). (C) 293FT cells transfected with 4 μ g of pHA-DDX3 (H), O cells (O), or RSc cells 3 days after inoculation of HCVcc (JFH1) (J) were lysed and immunoprecipitated (IP) with 1 μ g of anti-HA antibody (3F10), followed by immunoblotting with anti-HA (HA-7), anti-core (CP-9 and CP-11 mixture), or anti-HCV NS5A (no. 8926) and anti-HCV NS5B. (D) 293FT cells transfected with 4 μ g of pHA-DDX3 and 4 μ g of pcDNA3/FLAG-core(HCV-O) (wt), pcDNA3/FLAG- Δ core(HCV-O) (Δ), pcDNA3/FLAG-core(JFH1) (wt), or

on 30 μ l of protein G-Sepharose resin for 1 h, the resin was washed four times with 700 μ l lysis buffer. Proteins were eluted by boiling the resin for 5 min in 1 \times Laemmli sample buffer. The proteins were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblot analysis using either anti-HA (HA-7; Sigma) or anti-HCV core antibody (CP-9 and CP-11 mixture). We observed that the HCV-O core but not its N-truncated mutant could strongly bind to HA-tagged DDX3 (Fig. 2B). In contrast, the binding activity of the JFH1 core to HA-tagged DDX3 seemed to be fairly weak (Fig. 2B). As well, immunoprecipitation of lysates of 293FT cells expressing HA-tagged DDX3, O cells, or JFH1-infected RSc cells, or mixtures of these lysates, with an anti-HA antibody revealed that HCV-O core but not JFH1 core could bind strongly to DDX3 (Fig. 2C). The anti-HCV core antibody we used could detect both HCV-O core and JFH1 core (Fig. 2), while both anti-HCV NS5A and anti-NS5B antibodies failed to detect JFH1 NS5A and NS5B (Fig. 2C). At least, we failed to detect an interaction between DDX3 and either HCV-O NS5A or NS5B under experimental conditions that permitted the core to interact with DDX3 by immunoprecipitation (Fig. 2C). In contrast, the FLAG-tagged JFH1 core could bind to HA-tagged DDX3 just as efficiently as the FLAG-tagged HCV-O core could (Fig. 2D). Thus, the binding affinity or stability of the complex formed between the JFH1 core and DDX3 might be weaker than that between the HCV-O core and DDX3.

Since DDX3 is required for HIV-1 and HCV replication, we hypothesized that the HCV core might affect the function of HIV-1 Rev when both proteins were coexpressed. To test this hypothesis, we used the Rev-dependent luciferase-based reporter plasmid pDM628, harboring a single intron that includes both the Rev-responsive element (RRE) and the luciferase coding sequences (Fig. 3A) (10). In this system, Rev binds to RRE on the unspliced reporter mRNA, allowing its export from the nucleus for luciferase reporter gene expression, while the intron containing the luciferase gene is excised during RNA splicing when cells are transiently transfected with pDM628 alone. As previously reported (10), the luciferase activity in 293FT cells transfected with this reporter plasmid was stimulated by Rev, which induced a fourfold increase in the reporter signal (Fig. 3B). Luciferase activity was increased eightfold by the combination of Rev and DDX3, whereas neither the HCV-O core nor the JFH1 core had any effect on this Rev function (Fig. 3B). Since the Rev-binding domain (the N-terminal domain) and the core-binding domain (the C-terminal domain) do not overlap in DDX3, the HCV core might not compete with HIV-1 Rev for binding with DDX3. However, the development of a novel DDX3 inhibitor might provide a powerful antiviral agent against both HIV-1 and HCV (15).

Taking these results together, this study has shown for the first time that DDX3 is required for HCV RNA replication.

pcDNA3/FLAG- Δ core(JFH1) (Δ) were lysed and immunoprecipitated with 1 μ g of an anti-HA antibody (3F10), followed by immunoblotting with an anti-HA (HA-7) or anti-core (CP-9 and CP-11 mixture) antibody.




FIG. 3. HCV core does not affect the DDX3-mediated synergistic activation of Rev function. (A) Schematic representation of HIV-1 Rev-dependent luciferase-based reporter plasmid pDM628 harboring a splicing donor (SD), splicing acceptor (SA), and RRE. (B) 293FT cells were cotransfected with 100 ng of pDM628, 200 ng of pRev, 200 ng of pHA-DDX3, and/or 100 ng of either pcDNA3/core(HCV-O) (O) or pcDNA3/core(JFH1) (J). A luciferase assay was performed 24 h later. All transfections utilized equal total amounts of plasmid DNA owing to the addition of the empty vector pcDNA3 to the transfection mixture. The relative stimulation of luciferase activity (*n*-fold) is shown. The results shown are means from three independent experiments.

Since helicases are motor enzymes that use energy derived from nucleoside triphosphate hydrolysis to unwind double-stranded nucleic acids, the DDX3–core complex might unwind the HCV double-stranded RNA and separate the RNA strands or might contribute to the function of HCV NS3 helicase. Since the replication of subgenomic replicon RNA was also partially suppressed in DDX3 knockdown cells (Fig. 1D), DDX3 might be associated with an HCV nonstructural protein(s) or HCV RNA itself. Indeed, Tingting et al. recently reported that DDX1 bound to both the HCV 3' untranslated region (3' UTR) and the HCV 5' UTR and that short interfering RNA-mediated knockdown of DDX1 caused a marked reduction in the replication of subgenomic replicon RNA (22). Furthermore, Goh et al. demonstrated that DDX5/p68 associated with HCV NS5B and that depletion of endogenous DDX5 correlated with a reduction in the transcription of negative-strand HCV RNA (11). However, we failed to observe an interaction between DDX3 and NS5A or NS5B by immunoprecipitation under our experimental conditions in which the core could interact with DDX3 (Fig. 2C). Importantly, our DDX3 knockdown study demonstrated a more significant reduction in the accumulation of genome-length HCV RNA (95% reduction) than in the accumulation of subgenomic replicon RNA (52% reduction) (Fig. 1B and D). To date, it has been demonstrated that the 5' UTR, the 3' UTR, and the NS3-to-NS5B coding region are sufficient for HCV RNA replication (16); however, the core might be partly involved in the replication of genome-length HCV RNA. Importantly, DDX1 and DDX3 were specifically detected in the lipid droplets of core-expressing Hep39 cells by proteomic analysis (21), suggesting that DDX3 might be associated with HCV assembly or might incorporate into the HCV virion through interaction with the core to act as an RNA chaperone.

Recent studies have suggested a potential role of DDX3 and DDX5 in the pathogenesis of HCV-related liver diseases. DDX3 expression is deregulated in HCV-associated HCC (7, 8), and Huang et al. identified single-nucleotide polymorphisms in the DDX5 gene that were significantly associated with an increased risk of advanced fibrosis in patients with chronic hepatitis C (12). Interestingly, DDX3 might be a candidate tumor suppressor. DDX3 inhibits colony formation in various cell lines, including HuH-7, and up-regulates the p21^{waf1/cip1} promoter (8). If DDX3 could in fact suppress tumor growth, then the core might overcome DDX3-mediated cell growth arrest and down-regulate p21^{waf1/cip1} through interaction with DDX3, and it might also be involved in HCC development.

We thank D. Trono, K.-T. Jeang, V. Yedavalli, R. J. Pomerantz, J. Fang, R. Iggo, M. Hijikata, T. Akagi, and M. Kohara for pCMVΔR8.91, pMDG2, pHA-DDX3, pDM628, pcRev, pSUPER, pRDI292, 293FT cells, pCX4bsr, and the anti-NS5B antibody. We also thank A. Morishita and T. Nakamura for technical assistance.

This work was supported by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), by a Grant-in-Aid for Research on Hepatitis from the Ministry of Health, Labor, and Welfare of Japan, by the Naito Foundation, by the Ichiro Kanehara foundation, and by a research fellowship from the Japan Society for the Promotion of Science (JSPS).

REFERENCES

- Akagi, T., T. Shishido, K. Murata, and H. Hanafusa. 2000. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. *Proc. Natl. Acad. Sci. USA* **97**:7290–7295.
- Ariumi, Y., A. Kaida, M. Hatanaka, and K. Shimotohno. 2001. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. *Biochem. Biophys. Res. Commun.* **287**:556–561.
- Ariumi, Y., T. Ego, A. Kaida, M. Matsumoto, P. P. Pandolfi, and K. Shimotohno. 2003. Distinct nuclear body components, PML and SMRT, regulate the *trans*-acting function of HTLV-1 Tax oncoprotein. *Oncogene* **22**:1611–1619.
- Ariumi, Y., P. Turelli, M. Masutani, and D. Trono. 2005. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. *J. Virol.* **79**:2973–2978.
- Bridge, A. J., S. Pebernard, A. Ducraux, A.-L. Nicoluz, and R. Iggo. 2003. Induction of an interferon response by RNAi vectors in mammalian cells. *Nat. Genet.* **34**:263–264.
- Brummelkamp, T. R., R. Bernard, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**:550–553.
- Chang, P. C., C. W. Chi, G. Y. Chau, F. Y. Li, Y. H. Tsai, J. C. Wu, and Y. H. Lee. 2006. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. *Oncogene* **25**:1991–2003.
- Chao, C. H., C. M. Chen, P. L. Cheng, J. W. Shih, A. P. Tsou, and Y. H. Lee. 2006. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21^{waf1/cip1} promoter, is a candidate tumor suppressor. *Cancer Res.* **66**:6579–6588.
- Cordin, O., J. Banroques, N. K. Tanner, and P. Linder. 2006. The DEAD-box protein family of RNA helicases. *Gene* **367**:17–37.
- Fang, J., S. Kubota, B. Yang, N. Zhou, H. Zang, R. Godbout, and R. J. Pomerantz. 2004. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. *Virology* **330**:471–480.
- Goh, P. Y., Y. J. Tan, S. P. Lim, Y. H. Tan, S. G. Lim, F. Fuller-Pace, and W. Hong. 2004. Cellular RNA helicase p68 relocation and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. *J. Virol.* **78**:5288–5298.
- Huang, H., M. L. Shiffman, R. C. Cheung, T. J. Layden, S. Friedman, O. T. Abbar, L. Yee, A. P. Chokkalingam, S. J. Schrodli, J. Chan, J. J. Catanese, D. U. Leong, D. Ross, X. Hu, A. Monto, L. B. McAllister, S. Broder, T. White, J. J. Sninsky, and T. L. Wright. 2006. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. *Gastroenterology* **130**:1679–1687.
- Ikeda, M., K. Abe, H. Dansako, T. Nakamura, K. Naka, and N. Kato. 2005. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem. Biophys. Res. Commun.* **329**:1350–1359.
- Kato, N., K. Sugiyama, K. Namba, H. Dansako, T. Nakamura, M. Takami,

- K. Naka, A. Nozaki, and K. Shimotohno. 2003. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. *Biochem. Biophys. Res. Commun.* 306:756–766.
15. Kwong, A. D., B. G. Rao, and K. T. Jeang. 2005. Viral and cellular RNA helicases as antiviral targets. *Nat. Rev. Drug Discov.* 4:845–853.
 16. Lohmann, V., F. Körner, J.-O. Koch, U. Herian, L. Theilman, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113.
 17. Mamiya, N., and H. J. Worman. 1999. Hepatitis C virus core protein binds to a DEAD box RNA helicase. *J. Biol. Chem.* 274:15751–15756.
 18. Naldini, L., U. Blömer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. *Science* 272:263–267.
 19. Owsianka, A. M., and A. H. Patel. 1999. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. *Virology* 257:330–340.
 20. Rocak, S., and P. Linder. 2004. DEAD-box proteins: the driving forces behind RNA metabolism. *Nat. Rev. Mol. Cell Biol.* 5:232–241.
 21. Sato, S., M. Fukasawa, Y. Yamakawa, T. Natsume, T. Suzuki, I. Shoji, H. Aizaki, T. Miyamura, and M. Nishijima. 2006. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. *J. Biochem.* 139:921–930.
 22. Tingting, P., F. Caiyun, Y. Zhigang, Y. Pengyuan, and Y. Zhenghong. 2006. Subproteomic analysis of the cellular proteins associated with the 3' untranslated region of the hepatitis C virus genome in human liver cells. *Biochem. Biophys. Res. Commun.* 347:683–691.
 23. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Kräusslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
 24. Yedavalli, V. S., C. Neuveut, Y. H. Chi, L. Kleiman, and K. T. Jeang. 2004. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. *Cell* 119:381–392.
 25. You, L. R., C. M. Chen, T. S. Yeh, T. Y. Tsai, R. T. Mai, C. H. Lin, and Y. H. Lee. 1999. Hepatitis C virus core protein interacts with cellular putative RNA helicase. *J. Virol.* 73:2841–2853.
 26. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat. Biotechnol.* 15:871–875.

Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture[∇]

Masahiko Yano,^{1,2} Masanori Ikeda,^{1*} Ken-ichi Abe,¹ Hiromichi Dansako,¹ Shogo Ohkoshi,² Yutaka Aoyagi,² and Nobuyuki Kato¹

Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558,¹ and Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata City, 951-8510, Japan²

Received 15 November 2006/Returned for modification 1 February 2007/Accepted 29 March 2007

To date, only a limited number of studies have reported finding an influence of ordinary nutrients on hepatitis C virus (HCV) RNA replication. However, the effects of other nutrients on HCV RNA replication remain largely unknown. We recently developed a reporter assay system for genome-length HCV RNA replication in hepatoma-derived HuH-7 cells (OR6). Here, using this OR6 assay system, we comprehensively examined 46 nutrients from four nutrient groups: vitamins, amino acids, fatty acids, and salts. We found that three nutrients— β -carotene, vitamin D₂, and linoleic acid—inhibited HCV RNA replication and that their combination caused additive and/or synergistic effects on HCV RNA replication. In addition, combined treatment with each of the three nutrients and interferon alpha or beta or fluvastatin inhibited HCV RNA replication in an additive manner, while combined treatment with cyclosporine synergistically inhibited HCV RNA replication. In contrast, we found that vitamin E enhanced HCV RNA replication and negated the effects of the three anti-HCV nutrients and cyclosporine but not those of interferon or fluvastatin. These results will provide useful information for the treatment of chronic hepatitis C patients who also take anti-HCV nutrients as an adjunctive therapy in combination with interferon. In conclusion, among the ordinary nutrients tested, β -carotene, vitamin D₂, and linoleic acid possessed anti-HCV activity in a cell culture system, and these nutrients are therefore considered to be potential candidates for enhancing the effects of interferon therapy.

Hepatitis C virus (HCV) is a major pathogen of chronic hepatitis (CH) and leads to fatal liver diseases, such as liver cirrhosis and hepatocellular carcinoma (1, 23, 38). Approximately 170 million people worldwide are infected with HCV (40). Therefore, HCV infection is a global health problem. The combination of pegylated interferon (IFN) with ribavirin is currently the most effective therapy for CH C (11, 28), and long-term treatment has been shown to improve the sustained virological response (SVR) rate (37). However, the SVR rate still remains at approximately 55% (11). Combination therapy occasionally also causes adverse effects, such as severe anemia (10) and cerebral vascular lesions (7), and reduction of the dosage leads to insufficient treatment. These adverse effects are more serious in older patients. Therefore, it remains necessary to identify alternative agents that have fewer side effects to couple with IFN. In developing countries, it is difficult to administer expensive IFN therapy. Hence, in such countries, inexpensive anti-HCV reagents are especially desirable (36).

The lack of a small-animal model and a cell culture system to support efficient HCV RNA replication hampered the development of anti-HCV reagents. Since an HCV subgenomic replicon system was developed in 1999 (25), the mechanism of HCV RNA replication has been gradually elucidated by a number of groups (2). However, this subgenomic replicon sys-

tem may not necessarily reflect actual HCV RNA replication in hepatocyte cell lines, due to the absence of structural proteins. To overcome this problem, a cell culture system for genome-length HCV RNA replication was developed by several groups (4, 15, 33). We also developed a genome-length HCV RNA (strain O of genotype 1b) replication system (OR6) with luciferase as a reporter, which facilitated the prompt and precise monitoring of HCV RNA replication in hepatocyte cell lines (13, 30). In the OR6 assay system, the luciferase activity was well correlated with HCV RNA levels when cells were treated with IFN- α (13). Therefore, we quantified the luciferase activity instead of HCV RNA for the indirect evaluation of HCV RNA replication, although the OR6 assay system doesn't strictly quantify the HCV RNA replication. More recently, several groups have developed cell culture systems that produce infectious viral particles (genotype 2a), which can be used to reconstruct the life cycle of HCV infection in hepatocyte cell lines (24, 39, 45).

Using this OR6 assay system, we demonstrated that mizoribine (30), as an immunosuppressant, and fluvastatin (FLV) (14), as the reagent for hypercholesterolemia, inhibited HCV RNA replication in hepatocyte cell lines. Another immunosuppressant, cyclosporine (CsA), was also identified as an anti-HCV reagent in a subgenomic replicon system (41). These results suggested the expansion of the primary application of the existing therapeutic drugs to new anti-HCV therapy.

Other studies have also revealed that certain ordinary nutrients contained in common foods can influence HCV RNA replication (5, 8, 9, 17, 21, 26). However, in these studies, only a limited number of nutrients were tested. To date, there has

* Corresponding author. Mailing address: Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Phone: 81-86-235-7386. Fax: 81-86-235-7392. E-mail: maikeda@md.okayama-u.ac.jp.

[∇] Published ahead of print on 9 April 2007.




FIG. 1. Schematic gene organization of genome-length HCV RNA. (A) ORN/C-5B/KE RNA replicated in OR6 cells. RL (RLuc) is expressed as a fusion protein with neomycin phosphotransferase (NeoR). The position of an adaptive mutation, K1609E, is indicated by a black triangle. (B) Authentic HCV RNA, HCV-O/KE/EG, was introduced into the OR6c cells by electroporation as previously described (13). The positions of two adaptive mutations, E1202G and K1609E, are indicated by black triangles. IRES, internal ribosome entry site; EMCV, encephalomyocarditis virus.

been no comprehensive analysis of the effects of nutrients on HCV RNA replication. Thus, we inclusively investigated the effects of nutrients on genome-length HCV RNA replication using the OR6 assay system. Here, we report finding that three nutrients, namely, β -carotene (BC), vitamin D₂ (VD₂), and linoleic acid (LA), inhibited HCV RNA replication and that combination treatments including each of these nutrients and CsA synergistically inhibited HCV RNA replication. Furthermore, we found that vitamin E (VE) enhanced HCV RNA replication, and that the anti-HCV activities of each of the three nutrients and CsA were abrogated by VE.

MATERIALS AND METHODS

Reagents. Vitamin B₁₂, vitamin K₁ (VK1), vitamin K₂, elaidic acid, and vaccenic acid were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). BC, vitamin A (VA), vitamin B₁, vitamin B₂, vitamin B₃, vitamin B₆, vitamin C (VC), VD₂, vitamin D₃ (VD₃), VE, vitamin K₂ (VK2), pantothenic acid, biotin, folic acid, inositol, leucine, isoleucine, valine, tryptophan, phenylalanine, tyrosine, lauric acid, palmitic acid, stearic acid, behenic acid, oleic acid, elaidic acid, LA, arachidonic acid (AA), eicosapentaenoic acid (EPA), docosa-


hexaenoic acid (DHA), Fe(II)SO₄, Na₂SeO₄, Fe(III)(NO₃)₃, ZnCl₂, NaCl, KCl, CaCl₂, PCl₃, MgCl₂, CuCl₂, MnCl₂, and IFN- α were purchased from Sigma (St. Louis, MO), and CsA and FLV were purchased from Calbiochem (Los Angeles, CA). IFN- β was kindly provided by Toray Industries, Inc. Fatty acids, except for LA-albumin and oleic acid-albumin compounds (Sigma), were compounded with fatty acid-free bovine serum albumin (Sigma) as described in a previous report (6). We treated the HCV RNA-harboring cells at various concentrations of salts [Fe(II)SO₄ at 5, 25, and 50 μ M, Fe(III)(NO₃)₃ at 10, 100, and 200 μ M, ZnCl₂ at 20, 50, and 100 μ M, Na₂SeO₄ at 1, 2.5, and 5 μ M, NaCl at 100, 150, and 300 μ M, KCl at 5, 10, and 20 μ M, CaCl₂ at 2, 4, and 8 μ M, PCl₃ at 1, 2.5, and 5 μ M, MgCl₂ at 0.5, 2.5, and 5 μ M, CuCl₂ at 20, 50, and 100 μ M, and MnCl₂ at 30, 60, and 120 μ M]. Dimethyl sulfoxide or ethanol was used for the dissolution of the liposoluble nutrients, and the final concentrations (0.1%) of each were equal for the cells with nutrients and those without.

Cell cultures. OR6 cells, polyclonal genome-length HCV RNA (ORN/C-5B/KE)-replicating cells, and subgenomic replicon (ORN/3-5B/KE) cells, which were derived from hepatoma cell line, HuH-7, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin, streptomycin (designated as the control medium in this study), and G418 (300 μ g/ml) (Geneticin; Invitrogen, Carlsbad, CA), and the cells were passaged twice a week at a 5:1 split ratio. ORN/C-5B/KE and ORN/3-5B/KE are derived from HCV-O (strain O of genotype 1b). OR6c cells are cured OR6 cells from which

TABLE 1. Summary of anti-HCV activities of various nutrients

Nutrient type	Nutrient(s) with the indicated characteristic for HCV ^a		
	Inhibitory	Enhancing	Ineffective
Vitamins			
Liposoluble	BC, VD ₂	VA (retinol), VE, VK1, VK2, VK3	VD ₃
Water soluble		VC	VB1, VB2, VB3 (niacin), VB6, VB12, pantothenic acid, biotin, folic acid, inositol
Amino acids			
Branched-chain			Leucine, isoleucine, valine
Aromatic		Tryptophan	Phenylalanine, tyrosine
Fatty acids			
Saturated			Lauric acid (C ₁₂), palmitic acid (C ₁₆), stearic acid (C ₁₈), behenic acid (C ₂₂)
Mono-unsaturated			Oleic acid (C ₁₈ ; 9-unsaturated), elaidic acid (C ₁₈ ; trans-form of oleic acid), vaccenic acid (C ₁₈ ; 11-unsaturated)
Polyunsaturated	LA (C _{18:2} , n-6), AA (C _{20:4} , n-6), EPA (C _{20:5} , n-3), DHA (C _{22:6} , n-3)		
Salts	Fe(II)SO ₄ , Fe(III)(NO ₃) ₃ , ZnCl ₂	Na ₂ SeO ₄	NaCl, KCl, CaCl ₂ , PCl ₃ , MgCl ₂ , CuCl ₂ , MnCl ₂

^a Nutrients already contained in the medium are indicated in italics. VB1, vitamin B₁; VB2, vitamin B₂; VB3, vitamin B₃; VB6, vitamin B₆; VB12, vitamin B₁₂; VK3, vitamin K₃.



genome-length HCV RNA was eliminated by IFN- α treatment (500 IU/ml for 2 weeks) without G418, as previously described (13).

Luciferase reporter assay. For the *Renilla* luciferase (RL) assay, approximately 1.0×10^4 to 1.5×10^4 OR6 cells (72-hour treatment) or 0.5×10^4 OR6 cells (120-hour treatment) were plated onto 24-well plates in triplicate and cultured for 24 h. The cells were treated with each nutrient or compound for 72 or 120 h. Then, the cells were harvested with *Renilla* lysis reagent (Promega, Madison, WI) and subjected to the RL assay according to the manufacturer's protocol.

Western blot analysis. For Western blot analysis, 4×10^4 to 4.5×10^4 OR6c cells harboring HCV-O/KE/EG (strain O of genotype 1b) (K. Abe, M. Ikeda, and N. Kato, unpublished data) were plated onto six-well plates and cultured for 24 h and then were treated with each nutrient or compound for 72 h. Preparation of the cell lysates, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting were then performed as previously described (18). The antibodies used in this study were those specific to HCV core antigen (CP11; Institute of Immunology, Tokyo) and β -actin (Sigma). The epitope of CP11 was located within amino acid positions 21 to 40 of the core antigen. Immunocomplexes on the membranes were detected by enhanced chemiluminescence assay (Renaissance; Perkin Elmer Life Science, Wellesley, MA).

Cell viability. To examine the suppressive effects of nutrients on OR6 cell viability, approximately 4.5×10^4 to 5×10^4 OR6 cells (72-hour viability assay) or approximately 1×10^4 to 1.5×10^4 cells (120-hour viability assay) were plated onto six-well plates in triplicate and were cultured for 24 h. The cells were treated without nutrients or with each nutrient for 72 or 120 h, and then the number of viable cells was counted after trypan blue dye treatment as previously described (30).

Statistical analysis and synergistic statistics. Differences between the anti-HCV activities of the nutrients at each concentration and controls were tested using Student's *t* test. *P* values of less than 0.05 were considered statistically significant. Then, an isobologram method was used to evaluate the effects of a combination of nutrients or compounds on HCV RNA replication (21). OR6 cells were treated with each combination of nutrients or compounds at various concentrations for 72 h. The 50% effective concentration (EC_{50}) against HCV RNA replication in each combination treatment was analyzed by sigmoid regression, and isoboles of EC_{50} were plotted using the resulting data.

RESULTS

Effects of ordinary nutrients on HCV RNA replication. To date, information about the anti-HCV effects of ordinary nutrients has been limited to only a few studies, and in those studies, a plasmid (26), a subgenomic replicon (21), and recombinant HCV proteins (5, 8, 9) were used in the assays. We recently developed OR6 assay system by the selection after introducing genome-length ORN/C-5B/KE RNA (Fig. 1A) into HuH-7 cells. Our OR6 assay system renders it possible to carry out the prompt and precise evaluation of genome-length HCV RNA replication (13, 30). Therefore, we comprehensively analyzed 46 ordinary nutrients to determine their effects on HCV RNA replication using our novel OR6 assay system (Table 1). The effects of the preexistent nutrients in the medium on HCV RNA replication were under a significant level, because the concentrations of the nutrients already contained in the medium were less than a one-thousandth part of the minimum concentration in the treatment.

We first examined 8 liposoluble vitamins and 10 water-soluble vitamins to investigate their effects on HCV RNA repli-




FIG. 3. The anti-HCV activities of three nutrients were not due to the suppression of cell growth. Cell viabilities after treatment with BC, VD2, and LA are shown. OR6 cells were cultured in control medium [(-)] and in the presence of BC (5 and 10 μ M), VD2 (2.5 and 5 μ M), and LA (25 and 50 μ M) for 72 h, and then the number of viable cells was counted after trypan blue dye treatment. Shown here are the percent relative cell numbers calculated when the relative cell number of untreated cells was assigned as 100%. The data indicate means \pm SDs of triplicates from at least two independent experiments.

cation. Among the liposoluble vitamins, VA (Fig. 2D), VE (Fig. 2E), and VK (Fig. 2F and G) significantly enhanced HCV RNA replication. However, BC and VD2 significantly inhibited HCV RNA replication in a dose-dependent manner (the mean EC_{50} \pm standard deviations [SDs] were $6.3 \pm 0.7 \mu$ M and $3.8 \pm 0.9 \mu$ M, respectively) (Fig. 2A and B). In contrast with VD2, VD3 apparently enhanced relative luciferase activity, but this promotive effect was thought to result from cell proliferation, since the amount of β -actin increased in a manner similar to that of HCV core antigen (Fig. 2H). Most of the water-soluble vitamins exerted no effect on HCV RNA replication (data not shown), while only VC moderately enhanced HCV RNA replication (Fig. 2I).

We next examined three branched-chain amino acids and three aromatic amino acids for their effects on HCV RNA replication. We tested the six amino acids at concentrations of 0, 100, 500, and 1,000 μ M, and only tryptophan exerted moderate promotive effects on HCV RNA replication (Fig. 2J).

We further examined four saturated fatty acids, three mono-unsaturated fatty acids, and four polyunsaturated fatty acids (PUFAs) to assess their effects on HCV RNA replication. As has been noted in previous reports (17, 21), all of the PUFAs, i.e., LA, AA, EPA, and DHA, inhibited HCV RNA replication in OR6 cells in a dose-dependent manner (the mean EC_{50} \pm SDs were $20.2 \pm 4.8 \mu$ M, $22.1 \pm 1.7 \mu$ M, $36.2 \pm 2.5 \mu$ M, and $37.0 \pm 3.6 \mu$ M, respectively). However, we found that with the exception of LA, treatment with 50 μ M of PUFA resulted in

FIG. 2. Effects of ordinary nutrients on HCV RNA-replicating cells. (A through K) Reporter assay and Western blot analysis of nutrient sensitivity of HCV RNA replication. OR6 cells were treated with each nutrient at a four-grade-modulated concentration in the medium. After 72 h of treatment, the RL assay was performed as described in Materials and Methods. Shown here are the percent relative luciferase activities calculated when the RL activity of untreated cells was assigned the value of 100%. The data indicate means \pm SDs of triplicate samples from at least three independent experiments. Subsequently, OR6c cells, into which authentic HCV RNA was introduced, were treated with nutrients exhibiting either inhibitory effects, i.e., BC (A), VD2 (B), and LA (C), or promotive effects, i.e., VA (D), VE (E), VK1 (F), VK2 (G), VD3 (H), VC (I), tryptophan (J), and Se (K) at the same concentrations as those used in the OR6 assay (bar graphs). After 72 h of treatment, the production of HCV core antigen was analyzed by immunoblotting using antibody specific to HCV core antigen (upper lanes). β -Actin was used as a control for the amount of protein loaded per lane (lower lanes). *, *P* < 0.01; **, *P* < 0.05.




FIG. 4. The effects of BC, VD2, LA, and VE on polyclonal genome-length and subgenomic HCV RNA replication. Both polyclonal genome-length HCV RNA-replicating cells (ORN/C-5B/KE/poly) and subgenomic replicon cells (ORN/3-5B/KE/poly) were treated with BC, VD2, LA, or VE according to the same protocol as that used for the OR6 assay. The RL assay was performed at 72 h postapplication, and then RL activity was calculated as described in the legend to Fig. 2.

the suppression of cell growth due to cytotoxicity (data not shown). These data indicate that among PUFAs, only LA exhibited a significant inhibitory effect on HCV RNA replication without concomitant cytotoxicity (Fig. 2C and 3).

Finally, we examined 11 salts in order to assess their effects on HCV RNA replication. Iron [Fe(II) in the form of FeSO_4 and Fe(III) in the form of $\text{Fe}(\text{NO}_3)_3$] and zinc (in the form of ZnCl_2) exhibited anti-HCV effects without cytotoxicity at concentrations of up to 50% inhibition, but beyond 50% inhibition, cell growth was dose-dependently affected by the cytotoxicity of these minerals. Selenium (in the form of Na_2SeO_4), a typical antioxidant, slightly enhanced HCV RNA replication (Fig. 2K). We also confirmed these results using authentic HCV RNA-replicating cells (Fig. 1B and 2A through K).

These results suggest that the ordinary nutrients tested here have different profiles in terms of their effects on HCV RNA replication. The results are summarized in Table 1. Most of the nutrients were found to have no effect on HCV RNA replica-

tion. Eight nutrients enhanced HCV RNA replication, and the antioxidant nutrients VA, VC, VE, and Se were included in this group. Among the 46 nutrients tested with the OR6 assay system, we found that BC, VD2, and LA exerted anti-HCV effects without cytotoxicity. To the best of our knowledge, this is the first study to demonstrate the anti-HCV effects of BC and VD2. Therefore, we focused on the anti-HCV effects of BC, VD2, and LA in the following study.

The effects of BC, VD2, LA, and VE on polyclonal genome-length and subgenomic HCV RNA replication. OR6 cells are among the cloned cell lines selected by G418. Therefore, we examined polyclonal cells harboring genome-length HCV RNA (ORN/C-5B/KE/poly) to exclude the possibility that the anti-HCV effects of BC, VD2, and LA were an OR6 clone-specific phenomenon. Furthermore, polyclonal cells harboring subgenomic HCV RNA (ORN/3-5B/KE/poly) were also used to examine the effects of the anti-HCV nutrients on RNA replication in the absence of the structural HCV proteins. The

results revealed that all of these three nutrients exhibited a dose-dependent suppression of HCV RNA replication in both cell systems, although the three nutrients had stronger anti-HCV effects in the polyclonal genome-length HCV RNA-replicating cells than they did in the subgenomic HCV RNA-replicating cells (Fig. 4). These results indicated that the anti-HCV activities of these nutrients were not due to cell clonality, and the sensitivities of the reagents were found to differ between subgenomic and genome-length HCV RNA-replicating cells. One possible explanation of this difference is that the different genome sizes of subgenomic (9-kb) and genome-length (12-kb) HCV RNA might affect the replication efficiencies and lead to the difference in the sensitivities of antiviral reagents. These differences were significant, especially in BC- and LA-treated cells. A subgenomic replicon system may underestimate the effects of anti-HCV reagents and therefore might fail to identify potentially effective anti-HCV reagents. Therefore, our genome-length HCV RNA replication system (OR6) is advantageous for evaluating anti-HCV candidates.

We also tested VE's effect on subgenomic and genome-length HCV RNA-replicating cells. VE enhanced the replication of genome-length HCV RNA. However, interestingly, VE did not affect subgenomic HCV RNA replication. These results suggest that the subgenomic HCV RNA replication system may not be able to evaluate the reagent-enhancing HCV RNA replication.

Anti-HCV activities of three nutrients were not due to inhibition of cell growth. Since it has been reported that HCV RNA replication is dependent on cell growth (34), we examined whether the anti-HCV activities of three nutrients were due to their respective cytotoxicities. OR6 cells were treated with each nutrient (BC, 5 and 10 μ M; VD2, 2.5 and 5 μ M; LA, 25 and 50 μ M) for 72 h. These results suggest that the anti-HCV effects of BC, VD2, and LA are not due to their cytotoxicities.

Time course assay of inhibitory effects of three nutrients on HCV RNA replication. A kinetics analysis of the anti-HCV effects of reagents provides information about inhibitory mechanisms and optimized drug administration. Therefore, we conducted a time course assay (24, 72, and 120 h after treatment) of the anti-HCV effects of three nutrients, BC, VD2, and LA, using our OR6 assay system. The results revealed that BC and VD2 exhibited stronger inhibition of HCV RNA replication than did LA at 24 h after treatment. However, the anti-HCV activities of BC and VD2 only slightly increased at 72 or 120 h after treatment (Fig. 5A). On the other hand, LA inhibited HCV RNA replication in dose- and time-dependent manners. It is noteworthy that about 90% inhibition of RL activity was observed at 120 h after LA (50 μ M) treatment of OR6 cells (Fig. 5A).

We examined whether these reductions in relative RL activity induced by all three nutrients at 120 h were due to the suppression of cell growth. Compared to the number of untreated cells, at 120 h after treatment with each nutrient (BC, 5 and 10 μ M; VD2, 2.5 and 5 μ M; LA, 25 and 50 μ M), no significant reduction in the number of treated cells was observed (Fig. 5B). These results indicate that the anti-HCV effects of these three nutrients were not due to their respective cytotoxicities.




FIG. 5. Time course assay of the anti-HCV activities of three nutrients. (A) Time course of the inhibitory effects of three nutrients on HCV RNA replication. OR6 cells were treated with control medium [(-)], BC (5 and 10 μ M), VD2 (2.5 and 5 μ M), or LA (25 and 50 μ M), and the RL assay was performed at 24, 72, and 120 h postapplication. Relative RL activity was calculated as described in the legend to Fig. 2. (B) Time course of cell viability after the application of three nutrients. OR6 cells were cultured in the control medium and in the presence of BC (5 and 10 μ M), VD2 (2.5 and 5 μ M), or LA (25 and 50 μ M), and at 72 and 120 h postapplication, the number of viable cells was counted after trypan blue dye treatment. Shown here are the percent relative cell numbers calculated as described in the legend to Fig. 3.

HCV RNA replication was additively inhibited by each combination of three nutrients and was synergistically inhibited by all three. As described above, we found that BC, VD2, and LA possessed anti-HCV activities. However, these nutrients appeared to be insufficient for eliminating HCV by mono-treatment. Therefore, we examined the anti-HCV effects of two or three nutrients in combination.

To evaluate the effects of each combination treatment, OR6 cells were cotreated with two nutrients at the listed concentrations for 72 h (BC, approximately 0 to 5 μ M; VD2, approximately 0 to 3 μ M; LA, approximately 0 to 20 μ M). Isoles of 50% inhibition of HCV RNA replication were obtained for each data point. An analysis of the 50% isoboles of each combination treatment graphed nearly a straight line in each case. These results indicate that the inhibitory effects of all combinations on HCV RNA replication were additive (Fig. 6A).

Treatment with all three nutrients at various concentrations resulted in stronger suppression of HCV RNA replication in OR6 cells than we had predicted as an additive effect (Fig. 6B).




FIG. 6. Effects of treatment with each combination or all of the three nutrients on HCV RNA replication. (A) Isobole plots of 50% inhibition of HCV RNA replication. OR6 cells were treated with each combination of three nutrients, BC (0, 0.5, 1, 2, 3, 4, and 5 μM), VD2 (0, 0.1, 0.5, 1, 1.5, 2, and 3 μM), and LA (0, 1, 5, 10, 15, and 20 μM), for 72 h, and RL assay was performed as described in the legend to Fig. 2 to obtain 50% isoboles. The R^2 value indicates the coefficient of determination. (B) The effect of treatment with all three nutrients on HCV RNA replication was synergistic. OR6 cells were treated with LA (0, 10, and 20 μM) in addition to 2.5 μM BC plus 1 μM VD2, BC (0, 2.5, and 5 μM) in addition to 1 μM VD2 plus 20 μM LA, or VD2 (0, 1, and 2 μM) in addition to 2.5 μM BC plus 10 μM LA. After 72 h of treatment, the RL assay was performed, and then relative RL activity was calculated as described in the legend to Fig. 2.

For instance, in the sample cotreated with 2.5 μM BC ($\approx\text{EC}_{20}$) in addition to 1 μM VD2 ($\approx\text{EC}_{30}$) plus 20 μM LA ($\approx\text{EC}_{50}$) (Fig. 2A through C), the actual effect on HCV RNA replication was 90% inhibition, which was 20% greater than we had originally estimated (i.e., approximately 70%; $1 - 0.8 \times 0.7 \times 0.5 = 0.72$) (Fig. 6B). In addition, no suppression of cell growth was observed during these cotreatments (data not shown). These results suggest that treatment with a mixture of these three nutrients may exert synergistic inhibitory effects on HCV RNA replication.

Treatment with each of three nutrients in combination with IFN or FLV additively inhibited HCV RNA replication, and CsA synergistically inhibited HCV RNA replication. Recently, CsA was proposed as a novel candidate to be paired with IFN in similar studies using a cell culture system (41). We have also

reported findings obtained with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, statins, exerted diverse anti-HCV effects, and FLV was found to exert the strongest inhibitory effect on HCV RNA among the statins tested (14).

Therefore, we examined the anti-HCV effects of each of three nutrients in combination with IFN, FLV, or CsA by using OR6 cells. OR6 cells were treated for 72 h with IFN- α (0, 0.2, 0.5, and 1 IU/ml) in combination with each of the nutrients at various concentrations (BC, approximately 0 to 5 μM ; VD2, approximately 0 to 4 μM ; LA, approximately 0 to 20 μM) (Fig. 7A). FLV (approximately 0 to 2 μM) or CsA (approximately 0 to 1 $\mu\text{g/ml}$) was also used for treatment in combination with BC, VD2, or LA at the concentration mentioned above (Fig. 7B and C). Isoboles of 50% inhibition of HCV RNA replication were generated from each sample. An analysis of 50%








FIG. 7. Additive inhibitory effects of each of three nutrients in combination with IFN- α or FLV on HCV RNA replication, and synergistic effects observed with Cs. (A to C) Isobole plots of 50% inhibition of HCV RNA replication. OR6 cells were treated with BC (0, 1, 2, 3, 4, and 5 μ M), VD2 (0, 0.5, 1, 2, 3, and 4 μ M), and LA (0, 2.5, 5, 10, 15, and 20 μ M) in combination with IFN- α (0, 0.2, 0.5, and 1 IU/ml) (A), FLV (0, 0.5, 1, and 2 μ M) (B), or CsA (0, 0.2, 0.5, and 1 μ g/ml) (C) for 72 h, and the RL assay was performed as described in the legend to Fig. 2 to obtain 50% isoboles. The R^2 value indicates the coefficient of determination.



isoboles in combinations using each nutrient and IFN- α or FLV graphed nearly straight lines in each case, indicating that the suppressive effects of these cotreatments on HCV RNA replication were additive (Fig. 7A and B). Similar additive effects were obtained in combination with IFN- β (data not shown). It was noteworthy that all cotreatments with each nutrient and CsA resulted in curved, concave plots of 50% isoboles, thus suggesting that these combinations with CsA exerted synergistic inhibitory effects on HCV RNA replication (Fig. 7C). These results indicate that these three nutrients, administered as a supportive nutritional therapy, could potentially improve the SVR rate associated with IFN therapy alone.

The anti-HCV activities of BC, VD2, and LA, as well as that of CsA but not those of IFN and FLV, were completely canceled by VE. Among the 46 nutrients tested, BC and VD2 exhibited inhibitory effects on HCV RNA replication up to 70%, and LA exhibited inhibitory effects up to 90%, without exhibiting any cytotoxicity (Fig. 5A). In contrast, most of the liposoluble vitamins enhanced HCV RNA replication in OR6 cells. We used VE in the following studies because VE is one of the most common vitamins in the daily diet and it exerts a strong enhancing effect on HCV RNA replication. To clarify the mechanism of these opposing effects, we investigated whether the anti-HCV effects of BC, VD2, and LA were canceled by the addition of VE. We also tested representative anti-HCV compounds (i.e., CsA, IFN- α , IFN- β , and FLV) in combination with VE. We first examined the influence of 10 μ M VE on the nutrients and compounds at the 70% inhibitory concentration level (Fig. 8A and B). The inhibitory effects of IFN- α , IFN- β , and FLV were hardly influenced by cotreatment with VE, whereas the anti-HCV effects of BC, VD2, LA, and CsA were canceled to a significant level by VE in the OR6 cells (Fig. 8A, upper panel). These results were also confirmed using authentic HCV RNA-replicating cells (Fig. 8A, lower panel). To normalize these results, we divided the luciferase value observed in the presence of VE by that in the absence of VE, and we considered this value to represent the effects of VE. When this value was larger than the value obtained in the absence of anti-HCV reagent (2.0; column 1 in Fig. 8B), we interpreted it as indicative of a reagent whose anti-HCV effects were canceled by VE. According to this criterion, BC (4.1), VD2 (4.9), LA (5.6), and CsA (4.0) were evaluated to be reagents for which the anti-HCV effects were canceled by VE (columns 2, 3, 4, and 5 in Fig. 8B). The anti-HCV effects of IFN- α , IFN- β , and FLV were not affected by VE (columns 6, 7, and 8 in Fig. 8B). We next examined the influence of 10 μ M

VE on the anti-HCV nutrients and compounds at the 90% inhibitory concentration level (Fig. 8C and D). BC and VD2 were not assessed in this experiment, because the maximum inhibitory effect was 70% in the case of these nutrients (Fig. 5A). Similar results were obtained in this experiment. LA (10.8) and CsA (7.7) were evaluated to be reagents for which the anti-HCV effects were canceled by VE (compare columns 2 and 3 to column 1 in Fig. 8D), although IFN- α (2.8) and IFN- β (2.7) were slightly affected by VE at this concentration (Fig. 8D, compare columns 4 and 5 to column 1). Judging by these results, it appears that BC, VD2, LA, and CsA may share some mechanism by which VE negated their anti-HCV activities.

DISCUSSION

The differential effects of BC and VA, as well as those of VD2 and VD3, which belong to the same categories as VA and VD, respectively, are of interest. We observed that whereas BC and VD2 inhibited HCV RNA replication, VA enhanced it, and VD3 exhibited basically no effect. The mechanism governing how these vitamins from the same category exert different effects on HCV RNA remains to be elucidated. However, liposoluble vitamins have been reported to exhibit various physiological activities with each nuclear receptor, consequently acting as hormone-like substances (19, 20, 27, 35). Differences in the gene products induced by each of these vitamins may lead to differences in the effects on HCV RNA replication. Another explanation might be considered in the light of findings suggesting that VA is an antioxidant, and yet recently, BC has been reported to induce oxidative stress (32, 43). This diversity of activities among vitamins in the same category, VA, might result in a variety of influences on HCV RNA replication. Further studies are still needed to account for why these different consequences are generated.

Previous studies have demonstrated that PUFAs such as AA, EPA, and DHA inhibit HCV RNA replication in cell culture systems (17, 21). However, saturated and mono-unsaturated fatty acids have been shown to enhance HCV RNA replication (17). In the prior studies, the cells tolerated the presence of PUFAs at concentrations of up to 50 μ M. In contrast, in our study, 50 μ M PUFAs were toxic, with the exception of LA. Furthermore, saturated and mono-unsaturated fatty acids hardly exhibited any effects on HCV RNA replication in our OR6 cell culture system. These discrepancies might be due to differences in both the clonalities of the cells and the HCV strains used in each experiment.

FIG. 8. VE canceled the anti-HCV activities of BC, VD2, LA, and CsA. (A and B) Effects of VE on the nutrients and compounds at the 70% inhibitory concentration. Both OR6 cells and OR6c cells, into which authentic HCV RNA was introduced, were treated with control medium [(-)], 10 μ M BC, 5 μ M VD2, 30 μ M LA, 0.6 μ g/ml of CsA, 0.6 IU/ml of IFN- α , 0.4 IU/ml of IFN- β , or 1.2 μ M FLV in either the absence or presence of 10 μ M VE for 72 h. After treatment, an RL assay of harvested OR6 cell samples was performed, and then the relative RL activity was calculated as described in the legend to Fig. 2. Subsequently, the production of HCV core antigen in OR6c cells was analyzed by immunoblotting using antibody specific to HCV core antigen. β -Actin was used as a control for the amount of protein loaded per lane (A). Then, the ratio of RL activity in the presence of 10 μ M VE (+) to the RL activity in the absence of VE (-) was calculated. The horizontal line indicates the promotive effect of 10 μ M VE alone on HCV RNA replication as a baseline (B). (C and D) Effects of VE on the nutrients and compounds at the 90% inhibitory concentration. Both OR6 cells and OR6c cells were treated with control medium, 50 μ M LA, 1 μ g/ml of CsA, 1 IU/ml of IFN- α , 0.6 IU/ml of IFN- β , and 2 μ M FLV in either the absence (-) or presence (+) of 10 μ M VE for 72 h. After treatment, the RL assay and Western blot analysis were performed (C), and then the ratio of RL activity in the presence of 10 μ M VE to the RL activity in the absence of VE was calculated in the same manner as that described above (D).

Here, we demonstrated that three nutrients, BC, VD2, and LA, exhibited anti-HCV effects in polyclonal genome-length and subgenomic HCV RNA (strain O of genotype 1b)-replicating cells. These results indicated that the inhibitory activities of at least three anti-HCV nutrients are not limited to a specific cell clone (OR6).

Moreover, IFN or FLV exhibited additive anti-HCV effects when the cells were cotreated with each of the three anti-HCV nutrients. However, CsA showed synergistic anti-HCV effects in combination with each of these three nutrients. Interestingly, these results coincided with the experiment using VE, as VE canceled the anti-HCV effects of CsA but not those of IFN or FLV. It was recently demonstrated that the anti-HCV effects of CsA are related to the inhibition of cyclophilin (31, 42). CsA is also known as an oxidant that can cause renal or vascular dysfunction, and interestingly, antioxidants, including VE, attenuate these CsA-induced side effects (16, 22). Furthermore, we confirmed that another antioxidant, Se, also weakened the anti-HCV effects of BC, VD2, and LA (data not shown). Therefore, BC, VD2, and LA may possess an anti-HCV mechanism similar to that of CsA, and oxidative stress may be involved in these anti-HCV effects to some extent. Among the nutrients tested, VA, VC, VE, and Se enhanced HCV RNA replication, and these nutrients functioned as antioxidants. In contrast, four PUFAs inhibited HCV RNA replication, and they served as oxidants (29, 44). These results are further evidence of the involvement of oxidative stress in HCV RNA replication.

CH C patients may take excessive doses of VE during the course of interferon therapy, because as an antioxidant, VE has been expected to prevent injury to hepatocytes caused by oxidative stress. However, our results suggest that the potentially negative effects of VE on therapy for CH C patients should be carefully considered. To date, the significance of the role played by ordinary nutrients in viral infections has not been well characterized and has even been underestimated. We believe that our findings will shed light on the field of viral infection from the perspective of the nutritional sciences.

It is difficult to determine the blood concentrations of the nutrients tested in this study because the administration conditions may affect the concentrations in the blood. Rühl et al. (35) reported that the concentrations of BC in human serum are between 0.34 to 0.54 μM and that the average concentration in the human liver is 4.4 μM . Hagenlocher et al. (12) reported that the concentration of LA in human serum is 0.8 to 11.9 $\mu\text{g}/100 \mu\text{l}$. Armas et al. (3) reported that the concentration of VD2 in human serum at 24 h after a 50,000-IU administration is about 50 nM. The concentration of the nutrient in this study is higher than that in those reports. Therefore, monotreatment of the nutrient may not eliminate HCV. However, these nutrients may boost the effect of IFN treatment in combination like ribavirin does.

It is worth trying to examine the effects of BC, VD2, and LA on the recently developed JFH1 infectious virus production system in a future study. Here, it remains unclear whether these three nutrients affect the production of the virus. Furthermore, the comparison of the effects of these three nutrients between HCV genotypes 1 and 2 will provide useful information for the HCV therapy, as HCV genotypes 1 and 2 respond differentially to IFN treatment.

The precise mechanism underlying the anti-HCV activities of the nutrients has not been clarified in this study. The nutrients may inhibit viral RNAs and proteins, including the internal ribosome entry site, NS3-4A serine protease, and NS5B polymerase. Further in vitro study will be needed to clarify the targets of the nutrients responsible for their anti-HCV activities. Another possibility is that the nutrients inhibit the cellular proteins required for HCV RNA replication. We are now planning a study to clarify the mechanism underlying the nutrients' anti-HCV activities.

In conclusion, we found that three nutrients, BC, VD2, and LA, inhibited HCV RNA replication in a cell culture system and that Se, tryptophan, and various vitamins (A, C, E, and K) enhanced HCV RNA replication. The anti-HCV effects of BC, VD2, and LA were reversed by VE. These results are expected to provide useful information for the improvement of the SVR rates of patients receiving the currently standard IFN therapy. In addition, these findings may contribute to the development of a nutritional supplement specific to the treatment of people with CH C.

ACKNOWLEDGMENTS

We thank Atsumi Morishita for her technical assistance and Yasuo Ariumi for his helpful discussions.

This work was supported by a Grant-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control and by a Grant-in-Aid for research on hepatitis, both from the Ministry of Health, Labor, and Welfare of Japan. K.A. was supported by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists.

REFERENCES

- Alter, H. J., R. H. Purcell, J. W. Shih, J. C. Melpolder, M. Houghton, Q. L. Choo, and G. Kuo. 1989. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N. Engl. J. Med.* **321**:1494–1500.
- Appel, N., T. Schaller, F. Penin, and R. Bartenschlager. 2006. From structure to function: new insights into hepatitis C virus RNA replication. *J. Biol. Chem.* **281**:9833–9836.
- Armas, L. A., B. W. Hollis, and R. P. Heaney. 2004. Vitamin D2 is much less effective than vitamin D3 in humans. *J. Clin. Endocrinol. Metab.* **89**:5387–5391.
- Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J. Virol.* **76**:13001–13014.
- Bougie, I., S. Charpentier, and M. Bisailon. 2003. Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. *J. Biol. Chem.* **278**:3868–3875.
- Cousin, S. P., S. R. Hugl, C. E. Wrede, H. Kajio, M. G. Myers, Jr., and C. J. Rhodes. 2001. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. *Endocrinology* **142**:229–240.
- Ferencz, S., and R. Batey. 2003. Intracerebral haemorrhage and hepatitis C treatment. *J. Viral Hepat.* **10**:401–403.
- Ferrari, E., J. Wright-Minogue, J. W. Fang, B. M. Baroudy, J. Y. Lau, and Z. Hong. 1999. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in *Escherichia coli*. *J. Virol.* **73**:1649–1654.
- Fillebeen, C., A. M. Rivas-Estilla, M. Bisailon, P. Ponka, M. Muckenthaler, M. W. Hentze, A. E. Koromilas, and K. Pantopoulos. 2005. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus. *J. Biol. Chem.* **280**:9049–9057.
- Fried, M. W. 2002. Side effects of therapy of hepatitis C and their management. *Hepatology* **36**:S237–S44.
- Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, and A. M. Ackrill. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann. Intern. Med.* **140**:346–355.
- Hagenlocher, T., J. Nair, N. Becker, A. Korfmann, and H. Bartsch. 2001. Influence of dietary fatty acid, vegetable, and vitamin intake on etheno-DNA adducts in white blood cells of healthy female volunteers: a pilot study. *Cancer Epidemiol. Biomarkers Prev.* **10**:1187–1191.

13. Ikeda, M., K. Abe, H. Dansako, T. Nakamura, K. Naka, and N. Kato. 2005. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem. Biophys. Res. Commun.* 329:1350–1359.
14. Ikeda, M., K. Abe, M. Yamada, H. Dansako, K. Naka, and N. Kato. 2006. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. *Hepatology* 44:117–125.
15. Ikeda, M., M. Yi, K. Li, and S. M. Lemon. 2002. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. *J. Virol.* 76:2997–3006.
16. Jenkins, J. K., H. Huang, K. Ndebele, and A. K. Salahudeen. 2001. Vitamin E inhibits renal mRNA expression of COX II, HO I, TGFbeta, and osteopontin in the rat model of cyclosporine nephrotoxicity. *Transplantation* 71:331–334.
17. Kapadia, S. B., and F. V. Chisari. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. *Proc. Natl. Acad. Sci. USA* 102:2561–2566.
18. Kato, N., K. Sugiyama, K. Namba, H. Dansako, T. Nakamura, M. Takami, K. Naka, A. Nozaki, and K. Shimotohno. 2003. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. *Biochem. Biophys. Res. Commun.* 306:756–766.
19. Kiewer, S. A., J. M. Lehmann, and T. M. Willson. 1999. Orphan nuclear receptors: shifting endocrinology into reverse. *Science* 284:757–760.
20. Landes, N., P. Pfluger, D. Kluth, M. Birringer, R. Ruhl, G. F. Bol, H. Glatt, and R. Brigelius-Flohe. 2003. Vitamin E activates gene expression via the pregnane X receptor. *Biochem. Pharmacol.* 65:269–273.
21. Leu, G. Z., T. Y. Lin, and J. T. Hsu. 2004. Anti-HCV activities of selective polyunsaturated fatty acids. *Biochem. Biophys. Res. Commun.* 318:275–280.
22. Lexis, L. A., A. Fenning, L. Brown, R. G. Fassett, and J. S. Coombes. 2006. Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. *Am. J. Transplant.* 6:41–49.
23. Liang, T. J., L. J. Jeffers, K. R. Reddy, M. De Medina, I. T. Parker, H. Cheinquer, V. Idrovo, A. Rabassa, and E. R. Schiff. 1993. Viral pathogenesis of hepatocellular carcinoma in the United States. *Hepatology* 18:1326–1333.
24. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. *Science* 309:623–626.
25. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113.
26. Lott, W. B., S. S. Takyar, J. Tuppen, D. H. Crawford, M. Harrison, T. P. Sloots, and E. J. Gowans. 2001. Vitamin B12 and hepatitis C: molecular biology and human pathology. *Proc. Natl. Acad. Sci. USA* 98:4916–4921.
27. McDonnell, D. P., D. J. Mangelsdorf, J. W. Pike, M. R. Haussler, and B. W. O'Malley. 1987. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. *Science* 235:1214–1217.
28. McHutchison, J. G., and M. W. Fried. 2003. Current therapy for hepatitis C: pegylated interferon and ribavirin. *Clin. Liver Dis.* 7:149–161.
29. Miyamoto, S., G. R. Martinez, D. Rettori, O. Augusto, M. H. Medeiros, and P. Di Mascio. 2006. Linoleic acid hydroperoxide reacts with hypochlorous acid, generating peroxy radical intermediates and singlet molecular oxygen. *Proc. Natl. Acad. Sci. USA* 103:293–298.
30. Naka, K., M. Ikeda, K. Abe, H. Dansako, and N. Kato. 2005. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. *Biochem. Biophys. Res. Commun.* 330:871–879.
31. Nakagawa, M., N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C. H. Chen, S. Kakinuma, S. Oooka, S. Maekawa, N. Enomoto, and M. Watanabe. 2005. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. *Gastroenterology* 129:1031–1041.
32. Paolini, M., A. Antelli, L. Pozzetti, D. Spetlova, P. Perocco, L. Valgimigli, G. F. Pedulli, and G. Cantelli-Forti. 2001. Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. *Carcinogenesis* 22:1483–1495.
33. Pietschmann, T., V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, and R. Bartenschlager. 2002. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. *J. Virol.* 76:4008–4021.
34. Pietschmann, T., V. Lohmann, G. Rutter, K. Kurpanek, and R. Bartenschlager. 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. *J. Virol.* 75:1252–1264.
35. Rühl, R., R. Sczech, N. Landes, P. Pfluger, D. Kluth, and F. J. Schweigert. 2004. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. *Eur. J. Nutr.* 43:336–343.
36. Sagoe-Moses, C., R. D. Pearson, J. Perry, and J. Jagger. 2001. Risks to health care workers in developing countries. *N. Engl. J. Med.* 345:538–541.
37. Sánchez-Tapias, J. M., M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, R. Barcena, J. Crespo, R. Andrade, E. Martinez-Bauer, R. Perez, M. Testillano, R. Planas, R. Sola, M. Garcia-Bengochea, J. Garcia-Samaniego, M. Munoz-Sanchez, and R. Moreno-Otero. 2006. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology* 131:451–460.
38. Tong, M. J., N. S. el-Farra, A. R. Reikes, and R. L. Co. 1995. Clinical outcomes after transfusion-associated hepatitis C. *N. Engl. J. Med.* 332:1463–1466.
39. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
40. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin. Liver Dis.* 20:1–16.
41. Watashi, K., M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 38:1282–1288.
42. Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyazaki, and K. Shimotohno. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol. Cell* 19:111–122.
43. Yeh, S. L., W. Y. Wang, C. S. Huang, and M. L. Hu. 2006. Flavonoids suppresses the enhancing effect of beta-carotene on DNA damage induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A549 cells. *Chem. Biol. Interact.* 160:175–182.
44. Yin, H., E. S. Musiek, L. Gao, N. A. Porter, and J. D. Morrow. 2005. Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo. *J. Biol. Chem.* 280:26600–26611.
45. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. USA* 102:9294–9299.